Results 11 to 20 of about 876 (115)

Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis

Drug Delivery, 2022
Favipiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, is used to treat patients infected with influenza virus and most recently with SARS-CoV-2.
Ayca Yildiz Pekoz, Ozlem Akbal Dagistan, Hanan Fael, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Gokben Sahin, Muge Serhatli, Gamze Cakirca, Saban Tekin, Leyla Semiha Sen, Mustafa Sevim, Lutfiye Mulazimoglu Durmusoglu, Berrak C. Yegen   +13 more
doaj   +1 more source

Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals

Saudi Pharmaceutical Journal, 2023
Purpose: We aimed to evaluate the cost effectiveness of Favipiravir treatment versus standard of care (SC) in moderately to severely ill COVID-19 patients from the Saudi healthcare payer perspective.
Ahmad Alamer, Abdulaali R. Almutairi, Shiraz Halloush, Ahmed Al-jedai, Ahmed Alrashed, Mashael AlFaifi, Yahya Mohzari, Malak Almutairi, Fatimah AlHassar, Jude Howaidi, Wedad Almutairi, Ivo Abraham, Nimer Alkhatib   +12 more
doaj   +1 more source

Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.

PLoS Medicine, 2022
BackgroundEarly antiviral treatment is effective for Coronavirus Disease 2019 (COVID-19) but currently available agents are expensive. Favipiravir is routinely used in many countries, but efficacy is unproven.
David M Lowe, Li-An K Brown, Kashfia Chowdhury, Stephanie Davey, Philip Yee, Felicia Ikeji, Amalia Ndoutoumou, Divya Shah, Alexander Lennon, Abhulya Rai, Akosua A Agyeman, Anna Checkley, Nicola Longley, Hakim-Moulay Dehbi, Nick Freemantle, Judith Breuer, Judith Breuer, Joseph F Standing, FLARE Investigators   +18 more
doaj   +1 more source

A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test

International Journal of Infectious Diseases, 2021
As of October 2020, there is still no specific drug to treat COVID-19 as it rages worldwide. Favipiravir, indicated for the treatment of new and re-emerging influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not
Yushi Murai, Hitoshi Kawasuji, Yusuke Takegoshi, Makito Kaneda, Kou Kimoto, Akitoshi Ueno, Yuki Miyajima, Koyomi Kawago, Yasutaka Fukui, Chika Ogami, Ippei Sakamaki, Yasuhiro Tsuji, Yoshitomo Morinaga, Yoshihiro Yamamoto   +13 more
doaj   +1 more source

Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation

BMC Chemistry, 2023
Favipiravir and remdesivir have been included in the COVID-19 treatment guidelines panel of several countries. The main objective of the current work is to develop the first validated green spectrophotometric methods for the determination of favipiravir ...
Afnan S. Batubara, Ahmed H. Abdelazim, Ahmed A. Almrasy, Mohammed Gamal, Sherif Ramzy   +4 more
doaj   +1 more source

Determination of Favipiravir in Human Blood Plasma by HPLC-MS/MS

Разработка и регистрация лекарственных средств, 2023
Introduction. Favipiravir is one of the most well-known broad-spectrum drugs against many RNA viruses, including the severe acute respiratory syndrome virus 2 [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)].
T. N. Komarov, P. A. Karpova, O. A. Archakova, D. S. Shchelgacheva, P. K. Karnakova, N. S. Bagaeva, K. Ya. Zaslavskaya, P. A. Bely, I. E. Shohin   +8 more
doaj   +1 more source

Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. [PDF]

PLoS Neglected Tropical Diseases, 2013
Junín virus (JUNV), the etiologic agent of Argentine hemorrhagic fever (AHF), is classified by the NIAID and CDC as a Category A priority pathogen. Presently, antiviral therapy for AHF is limited to immune plasma, which is readily available only in the ...
Brian B Gowen, Terry L Juelich, Eric J Sefing, Trevor Brasel, Jennifer K Smith, Lihong Zhang, Bersabeh Tigabu, Terence E Hill, Tatyana Yun, Colette Pietzsch, Yousuke Furuta, Alexander N Freiberg   +11 more
doaj   +1 more source

STUDI EFEKTIVITAS DAN EFEK SAMPING FAVIPIRAVIR PADA PASIEN COVID-19 PNEUMONIA DI RUMAH SAKIT BHAYANGKARA SURABAYA

JIIS: Jurnal Ilmiah Ibnu Sina, 2023
Favipiravir merupakan antivirus untuk pengobatan COVID-19 karena mekanisme kerja obat atau efektivitasnya yang baik pada pasien COVID-19 dengan atau tanpa pneumonia.
Rika Yulia, Fauna Herawati, Klara Rosjuita Hima, Ruddy Hartono, Puri Safitri Hanum   +4 more
doaj   +1 more source

Conventional and synchronous spectrofluorometric determination of the recently administered drugs for treatment of COVID-19 favipiravir and apixaban

Scientific Reports, 2022
COVID-19 is a fast-spreading pandemic that is caused by SARS-CoV-2 viral pathogen. Combination therapy of the antiviral favipiravir and the anticoagulant apixaban is one of the efficient treatment regimens.
Heba Samir Elama, Abdallah M. Zeid, Shereen M. Shalan, Yasser El-Shabrawy, Manal I. Eid   +4 more
doaj   +1 more source

Development and Validation of HPLC-UV Method for the Determination of Favipiravir in Human Plasma

Разработка и регистрация лекарственных средств, 2022
Introduction. Coronavirus disease (COVID-19) is an acute infectious disease caused by SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2).
T. N. Komarov, P. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, N. S. Bagaeva, I. E. Shohin, K. Ya. Zaslavskaya, P. A. Bely   +7 more
doaj   +1 more source